Abstract
Immunotherapy has been suggested as a compelling alternative approach for conventional breast cancer treatment methods. Despite the paramount rolesof T cells in this approach, insufficient numbers of them in the combat against progressive tumor growth still remain to be dealt with. Super antigens are a class of antigens, capable of eliciting T cell proliferation response against desired antigens. Staphylococcal enterotoxin B (SEB) is categorized as a super antigen, its anti-tumor properties has been previously reported. However, to the best our knowledge, SEB has not been ever administered as a DNA construct. In the present study, we exploited bioinformatics tools to assess the immunoreactivity of a SEB-coding DNA construct that serves as a DNA vaccine for breast cancer therapy. Potential B and T (MHC class I and II binders) cell epitopes of the hypothetically expressed protein, along with its sub cellular localization were predicted. Moreover, probable glycosylation and phosphorylation sites within the protein sequence were determined. The gene sequence was optimized according to murine model codon bias and its mRNA stability was analyzed. Employing an integrative in silico approach, we revealed that apparently the construct could be efficiently expressed in mouse model. Moreover, the hypothetically expressed protein could act as an amenable adjuvant in cancer immunotherapy.
Similar content being viewed by others
Abbreviations
- BCG:
-
Bacillus Calmette–Guerin
- SAg:
-
Superantigens
- SEB:
-
Staphylococcal enterotoxin B
- MHC-II:
-
Histocomptability complex class II
- TCRs:
-
T cell receptors
- PTMs:
-
Post translational modifications
References
Abrahmsén L (1995) Superantigen engineering. Curr Opin Struct Biol 5(4):464–470
Alpaugh RK, Schultz J et al (1998) Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin Cancer Res 4(8):1903–1914
Amani J, Mousavi SL et al (2009) In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications. Theor Biol Med Model 6:28
Arcus VL, Proft T et al (2000) Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes1. J Mol Biol 299(1):157–168
Berger B, Stahlberg K et al (2011) Impact of radiotherapy, chemotherapy and surgery in multimodal treatment of locally advanced esophageal cancer. Int Soc Cell 81(5–6):387–394
Bhasin M, Raghava G (2004) Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine 22(23):3195–3204
Bhasin M, Raghava G (2007) A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes. J Biosciences 32(1):31–42
Borriello M, Laccetti P et al (2011) A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer 104(11):1716–1723
Brady S, Shatkay H (2008) EpiLoc: a (working) text-based system for predicting protein subcellular location. In: Pacific Symposium on Biocomputing. World Scientific, pp. 604–615
Briesemeister S, Blum T et al (2009) SherLoc2: a high-accuracy hybrid method for predicting subcellular localization of proteins. J Proteome Res 8(11):5363–5366
Chihara G, Maeda Y et al (1969) Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 222:687–688
Chou PY, Fasman GD (1977) Secondary structural prediction of proteins from their amino acid sequence. Trends Biochem Sci 2(6):128–131
Dougan DA, Micevski D et al (2012) The N-end rule pathway: from recognition by N-recognins, to destruction by AAA+proteases. Biochim et Biophysica Acta (BBA)—Mole Cell Res 1823(1):83–91
Emini EA, Hughes JV et al (1985) Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55(3):836–839
Erlandsson E, Andersson K et al (2003) dentification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol 333(5):893–905 I.
Fleischer B, Schrezenmeier H (1988) T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med 167(5):1697
Fooladi AAI, Nourani M (2009) Histological analysis antimetastatic effect of intera-venus injection of staphylococcal enterotoxin b and monophosphoryl lipid a against fibrosarchoma in lung tissue. J Iran Anat Sci 7:121–131
Fooladi AAI, Sattari M et al (2008) In vivo induction of necrosis in mice fibrosarcoma via intravenous injection of type B staphylococcal enterotoxin. Biotechnol Lett 30(12):2053–2059
Fooladi, I. A. A., Sattari M et al Synergistic effects between staphylococcal enterotoxin type B and monophosphoryl lipid A against mouse fibrosarcoma. J BUON 15(2): 340
Forsberg G, Ohlsson L et al (2001) Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 85(1):129
Fraser JD (2011) Clarifying the mechanism of superantigen toxicity. PLoS Biol 9(9):e1001145
Giantonio BJ, Alpaugh RK et al (1997) Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clinical Oncol 15(5):1994–2007
Hansson J, Ohlsson L et al (1997) Genetically engineered superantigens as tolerable antitumor agents. Proc Nat Acad Sci USA 94(6):2489
Horton P, Park K-J et al (2007) WoLF PSORT: protein localization predictor. Nucleic Acids Res 35(suppl 2): W585–W587
Hu J, Xuan X et al (2012) Anti-tumor function of double-promoter regulated adenovirus carrying SEA gene, in the treatment of bladder cancer. Cell Biochem Biophys: 1–7
Ishii KJ, Kawakami K et al (2003) Antitumor therapy with bacterial DNA and toxin. Clin Cancer Res 9(17):6516–6522
Jahangiri A, Rasooli I et al (2011). An in silico DNA vaccine against listeria monocytogenes. Vaccine 29:6948-6958
Jahangiri A, Rasooli I et al (2012). Precise detection of L. monocytogenes hitting its highly conserved region possessing several specific antibody binding sites. J Theor Biol
Jahangiri A, Rasooli I et al (2017) In silico design of an immunogen against Acinetobacter baumannii based on a novel model for native structure of Outer membrane protein A. Microb Pathog 105:201–210
Karplus P, Schulz G (1985) Prediction of chain flexibility in proteins. Naturwissenschaften 72(4):212–213
Kato M, Nakamura Y et al. (2011) Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells. Cancer Immunol Immunother 60:1–10
Khalili S, Jahangiri A et al (2014) Computational vaccinology and epitope vaccine design by immunoinformatics. Acta Microbiol Immunol Hung 61(3):285–307
Khalili S, Rahbar MR et al (2015) In silico analyses of Wilms tumor protein to designing a novel multi-epitope DNA vaccine against cancer. J Theor Biol 379:66–78
Khalili S, Jahangiri A et al (2017) Structural pierce into molecular mechanism underlying Clostridium perfringens epsilon toxin function. Toxicon. doi:10.1016/j.toxicon.2017
Khalili S, Rasaee MJ et al (2017) 3D structure of DKK1 indicates its involvement in both canonical and non-canonical Wnt pathways. Mol Biol 51(1):155–166
Kringelum JV, Lundegaard C et al (2012) Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol 8(12):e1002829
Lamm D, Stogdill V et al (1986) Complications of Bacillus Calmette–Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 135(2):272
Lanier LL (2001) A renaissance for the tumor immunosurveillance hypothesis. Nature Med 7(11):1178–1180
Larsen J, Lund O et al (2006) Improved method for predicting linear B-cell epitopes. Immunome Res 2(2):1–7
Larsen MV, Lundegaard C et al (2007) Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8(1):424
Laurila K, Vihinen M (2011) PROlocalizer: integrated web service for protein subcellular localization prediction. Amino Acids 40(3):975–980
LeClaire RD, Bavari S (2001) Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother 45(2):460–463
Lussow AR, MacDonald HR (1994) Differential effects of superantigen-induced “anergy” on priming and effector stages of a T cell-dependent antibody response. Eur J Immunol 24(2):445–449
Matsuda S, Vert J-P et al (2005) A novel representation of protein sequences for prediction of subcellular location using support vector machines. Protein Sci 14(11):2804–2813
Melief, C. J. M., R. E. M. Toes et al (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235–282
Miller C, Ragheb JA et al (1999) Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J Exp Med 190(1):53
Nakai K, Horton P (1999) PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci 24(1):34–35
Nothaft H, Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8(11):765–778
Ortega E, Abriouel H et al (2010) Multiple roles of Staphylococcus aureus enterotoxins: pathogenicity, superantigenic activity, and correlation to antibiotic resistance. Toxins 2(8):2117–2131
Papageorgiou AC, Tranter HS et al (1998a) Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol 277(1):61
Papageorgiou AC, Tranter HS et al (1998b) Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 Å resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors. J Mol Biol 277(1):61–79
Parker J, Guo D et al (1986) New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. BioChemistry 25(19):5425–5432
Pastan I, Chaudhary V et al (1992) Recombinant toxins as novel therapeutic agents. Annu Rev Biochem. doi:10.1146/annurev.bi.61.070192.001555
Patyar S., A. Prakash et al. (2012) Bacteria as a therapeutic approach in cancer therapy. in: Bacteria and cancer. Springer, Dordrecht, pp. 185–208
Perabo, F. G. E., Willert PL et al (2005) Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. Int J Cancer 115(4):591–598
Pesonen S, Diaconu I et al (2012) Oncolytic immunotherapy of advanced solid tumors with a CD40L expressing replicating adenovirus: assessment of safety and immunological responses in patients. Cancer Res 72:1621–1623
Ponomarenko J, Bui H-H et al (2008) ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinform 9(1):514
Proft T, Fraser JD (2003) Bacterial superantigens. Clin Exp Immunol 133(3):299–306
Reche PA, Reinherz EL (2007) Prediction of peptide-MHC binding using profiles. Methods Mol Biol 409:185–200
Reis LO, Ferreira U et al (2011) Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and Bacillus Calmette–Guérin immunotherapy for nonmuscle invasive bladder cancer. J Urol 187:438-445
Ren J, Wen L et al (2009) DOG 1.0: illustrator of protein domain structures. Cell Res 19(2):271–273
Rice J, Ottensmeier CH et al (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8(2):108–120
Rosendahl A, Hansson J et al (1996) Immune response during tumor therapy with antibody-superantigen fusion proteins. Int J Cancer 68(1):109–113
Sefid F, Rasooli I et al (2013) In silico determination and validation of baumannii acinetobactin utilization a structure and ligand binding site. BioMed Res Int. doi:10.1155/2013/172784
Sefid F, Rasooli I et al (2015) Functional exposed amino acids of BauA as potential immunogen against Acinetobacter baumannii. Acta Biotheor 63(2):129–149
Serbina NV, Salazar-Mather TP et al (2003) TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19(1):59–70
Siegel R, Ward E et al (2011) Cancer statistics, 2011.CA 6:212–236
Singh H, Raghava G (2003) ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 19(8):1009–1014
Singh H, Ansari HR et al (2013) Improved method for linear B-cell epitope prediction using antigen’s primary sequence. PLoS ONE 8(5):e62216
Smyth MJ, Godfrey DI et al (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2(4):293–299
Spaulding AR, Salgado-Pabón W et al (2013) Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26(3):422–447
Stevenson FK, Ottensmeier CH et al (2010) DNA vaccines against cancer come of age. Curr Opin Immunol 22(2):264–270
Sun Z, Shi L et al (2011) Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol 138(1):23–32
Swaminathan S, Furey W et al (1992) Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 359(6398):801–806
Tamura T, Akutsu T (2007) Subcellular location prediction of proteins using support vector machines with alignment of block sequences utilizing amino acid composition. BMC Bioinformatics 8(1):466
Tokunaga T, Yamamoto T et al (1999) How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 52(1):1
Toobak H, Rasooli I et al (2013) Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice. Biologicals 41(4):224–230
Tsai AK, Oh S et al (2011) A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neuro-Oncol 103(2):255–266
Varshney AK, Wang X et al (2011) Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock. J Biol Chem 286(11):9737–9747
Verma RS, Potala S et al (2012) Application of microbial toxins for cancer therapy. Microorganisms in sustainable agriculture and biotechnology. Springer, Dordrecht, pp. 647–662
Weldon JE, Pastan I (2011) A guide to taming a toxin–recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278(23):4683–4700
Xu M, Wang X et al (2011) An engineered superantigen SEC2 exhibits promising antitumor activity and low toxicity. Cancer Immunol Immunother 60(5):705–713
Yousefi F, Siadat SD et al (2016) Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy. Tumor Biol 37(4):5305–5316
Yu CS, Chen YC et al (2006) Prediction of protein subcellular localization. Proteins 64(3):643–651
Zhou X, Qiu J et al. (2012). “In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin. J Cancer Res Clin Oncol 138:1–10
Acknowledgements
This work was supported by the grant from the Applied Microbiology Research Center (AMRC) of Baqiyatallah University of Medical Sciences (BUMS).
Funding
This study was not funded by any grant form institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflict of interest declared.
Rights and permissions
About this article
Cite this article
Jahangiri, A., Amani, J., Halabian, R. et al. In Silico Analyses of Staphylococcal Enterotoxin B as a DNA Vaccine for Cancer Therapy. Int J Pept Res Ther 24, 131–142 (2018). https://doi.org/10.1007/s10989-017-9595-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-017-9595-3